70-85% of patients with Dravet syndrome have a mutation in the sodium channel gene SCN1A. Sodium channel blockers (lamotrigine, carbamazepine, phenytoin, etc.) can worsen seizures in patients with SCN1A gene mutations. All other options have other mechanisms of action and are known to be beneficial for patients with Dravet syndrome